HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David S. Starr Gerald M. Lawrie George C. Morris, Jr. Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Starr, D. S. Articles by Morris, G. C. Search for Related Content PubMed PubMed Citation Articles by Starr, D. S. Articles by Morris, G. C., Jr.

Ann Thorac Surg 1980;30:448-454
© 1980 The Society of Thoracic Surgeons

---

Articles

Clinical Experience with the Smeloff-Cutter Prosthesis: 1- to 12-Year Follow-up

From the Cora and Webb Mading Department of Surgery, Baylor College of Medicine, Houston, TX

^* Address reprint requests to Dr. Starr, 1393 Mt Everett Rd, Hubbard, OH 44425

To determine the long-term results of aortic valve replacement with the Smeloff-Cutter prosthesis, the fate of 358 of 459 (78%) consecutive patients was determined 1 to 12 years postoperatively. There were 319 male patients (70%). Mean age at operation was 57 years (range, 15 to 84 years). Aortic stenosis was the dominant lesion in 267 patients (58%) and aortic regurgitation in 133 patients (29%). Fifty-nine patients (13%) had both aortic stenosis and regurgitation. In addition to aortic valve replacement, 93 patients (20%) had coronary artery bypass, 30 (6.5%) had mitral commissurotomy, 23 (5%) had mitral valve replacement, and 41 (9%) had other procedures. Preoperative status by New York Heart Association Functional Class was: Class I, 3 (1%); Class II, 39 (8%); Class III, 148 (32%); and Class IV, 269 (59%). Operative (30-day) mortality was 8.5% (39 out of 459).

Functional improvement was obtained in all postoperative survivors: 345 (82%), Class I; 63 (15%), Class II; and 12 (3%), Class III. A perivalvular leak developed in 6 patients (1%) and subacute bacterial endocarditis in five (1%). Actuarial long-term survival was 80% at 5 years and 71% at 8 years. Thromboembolism occurred in 34 patients (9.5%). The incidence of thromboembolism per 100 patient-years for patients receiving no anticoagulants was 5.4; antiplatelet agents, 2.9; and Coumadin (sodium warfarin), 2.6. Major thromboembolism was uncommon in patients on a regimen of sodium warfarin but major morbidity from bleeding was significant.

This article has been cited by other articles:

				M.-S. Si and A. Zapolanski A 37-Year-Old Smeloff-Cutter Aortic Valve Ann. Thorac. Surg., February 1, 2009; 87(2): 628 - 629. [Abstract] [Full Text] [PDF]

				T. Suezawa, T. Morimoto, T. Jinno, and M. Tago Forty-Year Survival With Smeloff-Cutter and Starr-Edwards Prostheses Ann. Thorac. Surg., March 1, 2008; 85(3): e14 - e16. [Abstract] [Full Text] [PDF]

				A. S. Dunn, J. Wisnivesky, W. Ho, C. Moore, T. McGinn, and H. S. Sacks Perioperative Management of Patients on Oral Anticoagulants: A Decision Analysis Med Decis Making, July 1, 2005; 25(4): 387 - 397. [Abstract] [PDF]

				B. Gometza and C. M. G. Duran Ball valve (smeloff-cutter) aortic valve replacement without anticoagulation Ann. Thorac. Surg., November 1, 1995; 60(5): 1312 - 1316. [Abstract] [PDF]

				R. DeWall, L. C. Pelletier, A. Panebianco, G. Hicks, B. Schuster, R. Bonan, J.-P. Martineau, and L. Yip Five-Year Clinical Experience with the Omniscience Cardiac Valve Ann. Thorac. Surg., September 1, 1984; 38(3): 275 - 280. [Abstract] [PDF]

				C. G. Montero, J. J. Rufilanchas, A. Juffe, R. Burgos, J. Ugarte, and D. Figuera Long-Term Results of Cardiac Valve Replacement with the Delrin-Disc Model of the Bjork-Shiley Valve Prosthesis Ann. Thorac. Surg., April 1, 1984; 37(4): 328 - 336. [Abstract] [PDF]

				L. Nunez, M. G. Aguado, J. L. Larrea, D. Celemin, and J. Oliver Prevention of Thromboembolism Using Aspirin after Mitral Valve Replacement with Porcine Bioprosthesis Ann. Thorac. Surg., January 1, 1984; 37(1): 84 - 87. [Abstract] [PDF]

				W. Daenen, A. Nevelsteen, P. van Cauwelaert, E. de Maesschalk, J. Willems, and G. Stalpaert Nine Years' Experience with the Bjork-Shiley Prosthetic Valve: Early and Late Results of 932 Valve Replacements Ann. Thorac. Surg., June 1, 1983; 35(6): 651 - 663. [Abstract] [PDF]

				R. M. Becker, L. Sandor, M. Tindel, and R. W. M. Frater Medium-Term Follow-up of the Ionescu-Shiley Heterograft Valve Ann. Thorac. Surg., August 1, 1981; 32(2): 120 - 126. [Abstract] [PDF]